Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,848 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07443579Recruiting
Mammogram order study for breast cancer survivors
This trial tests if changing the order of mammogram views makes the exam more comfortable for women who have had breast cancer surgery and radiation. You may be able to join if you are due for your first check-up mammogram after finishing treatment.
Beaumont, DublinAges 18 years+ - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT06820255RecruitingPhase 4
DNA repair and platinum chemo for advanced bladder cancer
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
RomeAges 18 years+ - NCT07393555RecruitingPhase 2
Treatment for advanced lung cancer after targeted therapy and chemotherapy
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Berkeley, CaliforniaAges 18 years+ - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT06840067Recruiting
Carbon ion radiotherapy for pancreatic cancer
This trial tests a new type of radiation called carbon ion therapy for people with advanced pancreatic cancer (stages III–IV) that has spread or can't be removed by surgery. It's combined with standard chemotherapy (gemcitabine plus nituzumab) to see if it can help shrink tumors and improve outcomes.
Wuwei, GansuAges 18–80 - NCT07225270RecruitingPhase 3
Study of Rina-S plus care for ovarian cancer maintenance
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
Miami, FloridaAges 18 years+ - NCT07213570RecruitingPhase 2
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
Naples, ItalyAges 18 years+ - NCT05432518RecruitingEarly Phase 1
Pilot study for surgery and new medicine in recurrent glioblastoma
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
Calgary, AlbertaAges 18 years+ - NCT07171528RecruitingPhase 2
Surgery after chemo for recurrent ovarian cancer
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
Goyang-si, Gyeonggi-doAges 19–80 - NCT07167381Recruiting
Tumor testing to find cancer treatments for Florida patients
This study tests your tumor sample to find which drugs might work best for your cancer. It is for both children and adults whose cancer has come back or not responded to treatment, and who have already tried at least one standard therapy.
Miami, FloridaAges Any age - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+ - NCT07149649RecruitingPhase 2/Phase 3
Magnesium for advanced lung cancer
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
AarauAges 18 years+ - NCT05190094RecruitingPhase 2
Test blood-based laser scan to guide first-line breast cancer treatment
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
BlidaAges 18 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07098598RecruitingPhase 2/Phase 3
Using FAPI-PET to diagnose pancreatic cancer
This trial uses a special imaging scan called FAPI-PET to help doctors better diagnose pancreatic cancer. If you are suspected of having pancreatic cancer or a recurrence, this study may help confirm or clarify your diagnosis.
TurkuAges 18–85 - NCT07089641RecruitingPhase 1
Study of ERAS-801 for recurrent or newly diagnosed glioblastoma with EGFR changes
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07057102Recruiting
Gene testing to predict lung cancer treatment response and monitor recurrence
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07002203RecruitingPhase 1/Phase 2
Personalized cancer vaccine trial for solid tumors
This trial tests a custom-made vaccine designed to train your immune system to fight your specific cancer. It may be an option if you have advanced cancer that stopped responding to treatment or early-stage cancer with a high risk of coming back.
BangkokAges 20 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT06923826RecruitingPhase 2
Study of sacituzumab govitecan for advanced salivary gland and thyroid cancers
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
SingaporeAges 21 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,848 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.